View in EDS

A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.

Saved in:
Bibliographic Details
Title: A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
Authors: Spiera R; Weill Cornell Medical College, New York City, NY, USA. SpieraR@hss.edu., Khanna D; University of Michigan Scleroderma Program, Ann Arbor, MI, USA., Kuwana M; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan., Furst DE; Department of Rheumatology, University of California in Los Angeles, CA, USA., Frech TM; University of Utah and Salt Lake City VA Health Care System Salt Lake City, UT, USA., Hummers L; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA., Stevens W; Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia., Matucci-Cerinic M; Department of Experimental Rheumatology, University of Florence and Division of Rheumatology AOUC, Florence, Italy., Baron M; Division of Rheumatology, Jewish General Hospital, Montreal, Canada., Distler O; Department of Rheumatology, University Hospital Zurich, Switzerland., Dgetluck N; Corbus Pharmaceuticals, Inc. Norwood, MA, USA., Bloom BJ; Corbus Pharmaceuticals, Inc. Norwood, MA, USA., Dinh Q; Corbus Pharmaceuticals, Inc. Norwood, MA, USA., White B; Corbus Pharmaceuticals, Inc. Norwood, MA, USA., Denton CP; UCL Centre for Rheumatology and Connective Tissue Diseases, Royal Free Campus, University College London, UK.
Source: Clinical and experimental rheumatology [Clin Exp Rheumatol] 2021 Jul-Aug; Vol. 39 Suppl 131 (4), pp. 124-133. Date of Electronic Publication: 2021 Jul 21.
Publication Type: Journal Article; Clinical Trial Protocol
Journal Info: Publisher: Clinical And Experimental Rheumatology S.A.S Country of Publication: Italy NLM ID: 8308521 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0392-856X (Print) Linking ISSN: 0392856X NLM ISO Abbreviation: Clin Exp Rheumatol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 34323681
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Spiera+R%22">Spiera R</searchLink>; Weill Cornell Medical College, New York City, NY, USA. SpieraR@hss.edu.<br /><searchLink fieldCode="AU" term="%22Khanna+D%22">Khanna D</searchLink>; University of Michigan Scleroderma Program, Ann Arbor, MI, USA.<br /><searchLink fieldCode="AU" term="%22Kuwana+M%22">Kuwana M</searchLink>; Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine, Tokyo, Japan.<br /><searchLink fieldCode="AU" term="%22Furst+DE%22">Furst DE</searchLink>; Department of Rheumatology, University of California in Los Angeles, CA, USA.<br /><searchLink fieldCode="AU" term="%22Frech+TM%22">Frech TM</searchLink>; University of Utah and Salt Lake City VA Health Care System Salt Lake City, UT, USA.<br /><searchLink fieldCode="AU" term="%22Hummers+L%22">Hummers L</searchLink>; Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.<br /><searchLink fieldCode="AU" term="%22Stevens+W%22">Stevens W</searchLink>; Department of Rheumatology, St Vincent's Hospital, Melbourne, Victoria, Australia.<br /><searchLink fieldCode="AU" term="%22Matucci-Cerinic+M%22">Matucci-Cerinic M</searchLink>; Department of Experimental Rheumatology, University of Florence and Division of Rheumatology AOUC, Florence, Italy.<br /><searchLink fieldCode="AU" term="%22Baron+M%22">Baron M</searchLink>; Division of Rheumatology, Jewish General Hospital, Montreal, Canada.<br /><searchLink fieldCode="AU" term="%22Distler+O%22">Distler O</searchLink>; Department of Rheumatology, University Hospital Zurich, Switzerland.<br /><searchLink fieldCode="AU" term="%22Dgetluck+N%22">Dgetluck N</searchLink>; Corbus Pharmaceuticals, Inc. Norwood, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bloom+BJ%22">Bloom BJ</searchLink>; Corbus Pharmaceuticals, Inc. Norwood, MA, USA.<br /><searchLink fieldCode="AU" term="%22Dinh+Q%22">Dinh Q</searchLink>; Corbus Pharmaceuticals, Inc. Norwood, MA, USA.<br /><searchLink fieldCode="AU" term="%22White+B%22">White B</searchLink>; Corbus Pharmaceuticals, Inc. Norwood, MA, USA.<br /><searchLink fieldCode="AU" term="%22Denton+CP%22">Denton CP</searchLink>; UCL Centre for Rheumatology and Connective Tissue Diseases, Royal Free Campus, University College London, UK.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228308521%22">Clinical and experimental rheumatology</searchLink> [Clin Exp Rheumatol] 2021 Jul-Aug; Vol. 39 Suppl 131 (4), pp. 124-133. <i>Date of Electronic Publication: </i>2021 Jul 21.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial Protocol
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Clinical+And+Experimental+Rheumatology+S%2EA%2ES%22">Clinical And Experimental Rheumatology S.A.S </searchLink><i>Country of Publication: </i>Italy <i>NLM ID: </i>8308521 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>0392-856X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220392856X%22">0392856X </searchLink><i>NLM ISO Abbreviation: </i>Clin Exp Rheumatol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=34323681
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.55563/clinexprheumatol/i80zh7
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 124
    Titles:
      – TitleFull: A randomised, double-blind, placebo-controlled phase 3 study of lenabasum in diffuse cutaneous systemic sclerosis: RESOLVE-1 design and rationale.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Spiera R
      – PersonEntity:
          Name:
            NameFull: Khanna D
      – PersonEntity:
          Name:
            NameFull: Kuwana M
      – PersonEntity:
          Name:
            NameFull: Furst DE
      – PersonEntity:
          Name:
            NameFull: Frech TM
      – PersonEntity:
          Name:
            NameFull: Hummers L
      – PersonEntity:
          Name:
            NameFull: Stevens W
      – PersonEntity:
          Name:
            NameFull: Matucci-Cerinic M
      – PersonEntity:
          Name:
            NameFull: Baron M
      – PersonEntity:
          Name:
            NameFull: Distler O
      – PersonEntity:
          Name:
            NameFull: Dgetluck N
      – PersonEntity:
          Name:
            NameFull: Bloom BJ
      – PersonEntity:
          Name:
            NameFull: Dinh Q
      – PersonEntity:
          Name:
            NameFull: White B
      – PersonEntity:
          Name:
            NameFull: Denton CP
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 07
              Text: 2021 Jul-Aug
              Type: published
              Y: 2021
          Identifiers:
            – Type: issn-print
              Value: 0392-856X
          Numbering:
            – Type: volume
              Value: 39 Suppl 131
            – Type: issue
              Value: 4
          Titles:
            – TitleFull: Clinical and experimental rheumatology
              Type: main
ResultId 1